PanGIA Biotech–a pioneer in liquid biopsy technology–today announced its first international partnership, collaborating with Canary Oncoceutics (Canary Oncoceutics, Inc., Phoenix, AZ, and Canary Oncoceutics India Pvt Ltd, Tamil Nadu, India). This collaboration introduces the PanGIA Prostate Assay, the world’s first AI-integrated urine-based liquid biopsy for prostate cancer detection, marking its commercial debut in India.
“Launching our patented PanGIA Prostate Assay in India marks an important milestone for our company and healthcare innovation. This non-invasive, accurate, and culturally sensitive diagnostic tool is poised to enhance early prostate cancer detection and improve patient outcomes,” said Holly Magliochetti, CEO of PanGIA Biotech. “Partnering with Canary Oncoceutics enables us to bring life-changing technology to a population in need, reinforcing our commitment to saving lives, changing lives, and giving back by advancing healthcare equity.”
A Turning Point in Early Cancer Detection in India
The World Health Organization’s Global Cancer Observatory (GLOBOCAN) estimates that prostate cancer is a significant health concern for men in India. Hebert, et al reported that about 85 percent of prostate cancers in India were detected at late (III and IV) stage; in contrast to the U.S. where 15 percent of prostate cancer is diagnosed at late stage. These figures highlight the importance of early detection for improving outcomes and reducing mortality rates. “The only way to mitigate the harm caused by rising case numbers is to urgently set up systems for earlier diagnosis in Low and Middle Income Countries,” according to the Lancet Commission on Prostate Cancer (2024).
“With this partnership agreement, we can offer a unique test to the medical community in India,” said Dr. Harry Lander, CEO and co-founder of Canary Oncoceutics, Inc. “Our extensive presence in India allows us to rapidly deploy the PanGIA Prostate Assay.”
PanGIA Biotech is actively advancing its R&D pipeline, targeting ten additional cancers including lung, pancreatic, ovarian, and breast. The company is also focused on validating its multi-cancer assay and expanding its global impact through continued innovation, offering long-term growth potential for partners.
